Cidara Therapeutics, Inc.

NasdaqCM:CDTX Stock Report

Market Cap: US$7.0b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Cidara Therapeutics Future Growth

Future criteria checks 2/6

Cidara Therapeutics is forecast to grow earnings and revenue by 51.9% and 62.4% per annum respectively. EPS is expected to grow by 54.1% per annum. Return on equity is forecast to be -70.2% in 3 years.

Key information

51.9%

Earnings growth rate

54.15%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate62.4%
Future return on equity-70.18%
Analyst coverage

Good

Last updated28 Nov 2025

Recent future growth updates

Recent updates

New Narrative • Mar 05

Expanded Phase III Trial And BARDA Support Will Shape Long Term Outlook

Catalysts About Cidara Therapeutics Cidara Therapeutics develops drug Fc conjugates aimed at preventing and treating serious infectious diseases such as influenza. What are the underlying business or industry changes driving this perspective?
Seeking Alpha • Dec 29

Cidara: Merck's Acquisition Based On CD388 Flu Prevention Potential

Summary Cidara Therapeutics delivered a 1,165%+ return, driven by positive CD388 data and Merck's $221.50/share acquisition offer. CD388 achieved statistically significant prevention efficacy up to 76% in phase 2b, leading to FDA alignment for the single pivotal phase 3 ANCHOR trial. Phase 3 ANCHOR trial reached 6,000-patient enrollment; interim analysis is expected Q1 2026, with BLA submission contingent on success for this and subsequent Southern Hemisphere study start. I maintain a "Hold" rating as the Merck acquisition awaits HSR clearance, with regulatory and competitive risks remaining. Plus, no further upside as the acquisition is already announced. Read the full article on Seeking Alpha
Seeking Alpha • Feb 11

Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention

Summary Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388’s safety and efficacy. CD388 inhibits viral replication and activates the immune response, and its mechanism of action actually received the FDA’s Fast Track designation. Interestingly, CDTX reduced its workforce by 30% to concentrate on CD388. This could very well pay off if they're successful with their 2025 trials. Overall, CDTX stock trades at a reasonable valuation, so I feel it’s fair to give it a speculative “Buy” rating as a bet on CD388 in 2025. Read the full article on Seeking Alpha
New Narrative • Jan 13

Cidara Therapeutics: The underestimated potential of CD388

CD388 is a universal long-lasting influenza drug against all seasonal and pandemic influenza viruses in a phase 2b clinical trial. CD388 is not a vaccine but would provide 6 months of protection.
Seeking Alpha • Oct 04

Cidara spikes on $11M milestone payment from partner Mundipharma

The shares of clinical-stage biotech Cidara Therapeutics (NASDAQ:CDTX) gained over 8% pre-market Tuesday after the company announced that British drugmaker Mundipharma paid $11.1M as a milestone payment under a 2019 licensing deal. The payment follows the acceptance of the marketing authorization application (MAA) for rezafungin by the European Medicines Agency (EMA) as a treatment for fungal diseases candidemia and invasive candidiasis. While CDTX has rights for rezafungin in Japan, the company has sold the U.S. commercial rights for the drug to Melinta Therapeutics and rights for all other territories to Mundipharma. Chief Executive Jeffrey Stein said that his company remains on track to receive up to ~$108M in milestone payments as additional non-dilutive capital from partners subject to the accomplishment of events scheduled for the next two years. Read more about the CDTX’s licensing deal for rezafungin with Melinta in the U.S.
Seeking Alpha • Sep 13

Cidara begins dosing of antiviral CD388 in trial for preventing influenza

Cidara Therapeutics (NASDAQ:CDTX) said it began dosing in a phase 2a trial of CD388 to evaluate the pre-exposure prophylactic activity of the antiviral against influenza virus. CD388 is aimed to deliver universal prevention of seasonal and pandemic influenza, the company said in A a Sept. 13 press release. Cidara said the study is being conducted under an exclusive worldwide license and collaboration with Johnson & Johnson (NYSE:JNJ), to develop and commercialize Cidara's Cloudbreak drug-Fc conjugates (DFCs) to prevent seasonal and pandemic influenza. Multiple dose levels of CD388 will be evaluated in people who will receive a single administration of CD388 or placebo prior to influenza viral challenge. The trial is expected to enroll up to 168 healthy adults. "Because of its mode of action, CD388 has the potential to enable universal influenza coverage against all viral strains for all people, including those with compromised immune systems. We look forward to announcing the findings next year, and continuing our collaboration with Janssen who will be spearheading late-stage development," said Cidara President and CEO Jeffrey Stein.
Seeking Alpha • Aug 09

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Cidara Therapeutics press release (NASDAQ:CDTX): Q2 GAAP EPS of -$0.19 beats by $0.09. Revenue of $6.22M (-81.1% Y/Y) beats by $0.01M.

Earnings and Revenue Growth Forecasts

NasdaqCM:CDTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20283833-35N/A4
12/31/202712-217-147-1386
12/31/202610-172-131-3116
12/31/2025N/A-179-151-1185
9/30/2025N/A-185-133-133N/A
6/30/2025N/A-117-129-129N/A
3/31/20250-186-192-192N/A
12/31/20241-170-177-177N/A
9/30/20244-126-160-160N/A
6/30/202413-114-125-125N/A
3/31/202418-26-19-18N/A
12/31/202323-25-23-22N/A
9/30/202331-34-31-31N/A
6/30/202362-18-1-1N/A
3/31/202364-22-16-16N/A
12/31/202223-22-29-28N/A
9/30/202261-33-22-22N/A
6/30/202228-63-62-62N/A
3/31/202254-44-47-47N/A
12/31/202150-42-25-25N/A
9/30/202146-47-21-21N/A
6/30/202141-47-24-24N/A
3/31/202112-74-41-41N/A
12/31/202012-75-55-54N/A
9/30/202010-67-59-58N/A
6/30/202027-47-28-28N/A
3/31/202023-42-27-27N/A
12/31/201921-41-29-29N/A
9/30/201919-39-27-27N/A
6/30/2019N/A-56N/A-56N/A
3/31/2019N/A-69N/A-59N/A
12/31/2018N/A-69N/A-57N/A
9/30/2018N/A-70N/A-53N/A
6/30/2018N/A-69N/A-54N/A
3/31/2018N/A-59N/A-50N/A
12/31/2017N/A-56N/A-50N/A
9/30/2017N/A-57N/A-52N/A
6/30/2017N/A-57N/A-46N/A
3/31/2017N/A-52N/A-43N/A
12/31/2016N/A-48N/A-40N/A
9/30/2016N/A-44N/A-35N/A
6/30/2016N/A-41N/A-34N/A
3/31/2016N/A-35N/A-31N/A
12/31/2015N/A-32N/A-26N/A
9/30/2015N/A-27N/A-22N/A
6/30/2015N/A-21N/A-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CDTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CDTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CDTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CDTX's revenue (62.4% per year) is forecast to grow faster than the US market (10.4% per year).

High Growth Revenue: CDTX's revenue (62.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CDTX is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/06 23:35
End of Day Share Price 2026/01/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cidara Therapeutics, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Timothy ChiangBTIG
Eun Kyung YangJefferies LLC
Kevin DeGeeterLadenburg Thalmann & Company